Compare VNRX & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | CDLX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 26.0M |
| IPO Year | 2012 | 2018 |
| Metric | VNRX | CDLX |
|---|---|---|
| Price | $1.34 | $4.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $1.67 | ★ $2.25 |
| AVG Volume (30 Days) | ★ 237.1K | 68.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 50.13 |
| EPS | ★ N/A | N/A |
| Revenue | $1,727,384.00 | ★ $233,273,000.00 |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | $8.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.55 |
| 52 Week High | $3.26 | $6.40 |
| Indicator | VNRX | CDLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 55.36 |
| Support Level | $1.30 | $0.78 |
| Resistance Level | $1.56 | $6.40 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | 0.02 | -0.25 |
| Stochastic Oscillator | 59.68 | 17.22 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.